Regeneron Pharmaceuticals REGN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Lynozyfic | $11.2M— | —— | —— | —— | $0— | |
| Other products | $31.3M+237% | $9.3M+1,063% | $800K— | $0— | $0— | |
| (Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, net | -$16.7M-32.5% | -$12.6M+46.4% | -$23.5M-30.6% | -$18M-16.1% | -$15.5M-37.2% | |
| Reimbursement For Manufacturing Of Commercial Supplies | $154.3M0.0% | $154.3M-4.5% | $161.5M0.0% | $161.5M-2.1% | $165M-2.8% | |
| Reimbursement Of Commercialization Related Expenses | $184.1M-4.9% | $193.5M+6.0% | $182.6M-5.9% | $194M+21.9% | $159.2M-18.8% | |
| Cost of goods sold, collaboration and contract manufacturing by Product | ||||||
| Collaborationand Contract Manufacturing | $296M+11.3% | $265.9M+10.5% | $240.6M-5.5% | $254.6M+28.1% | $198.8M-16.7% | |
| Product | $373.4M+17.2% | $318.7M+13.4% | $281M+2.0% | $275.6M+3.8% | $265.5M-18.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Regeneron Pharmaceuticals break its business down?
- Regeneron Pharmaceuticals (REGN) reports revenue by product across 5 parts — Lynozyfic, Other products, (Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, net, Reimbursement For Manufacturing Of Commercial Supplies and Reimbursement Of Commercialization Related Expenses. Each is extracted from the segment footnotes and tracked over time.
- Where does Regeneron Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Regeneron Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
